204 related articles for article (PubMed ID: 35419609)
1. Anti-tumor immunity by transcriptional synergy between TLR9 and STING activation.
Temizoz B; Hioki K; Kobari S; Jounai N; Kusakabe T; Lee MSJ; Coban C; Kuroda E; Ishii KJ
Int Immunol; 2022 Jul; 34(7):353-364. PubMed ID: 35419609
[TBL] [Abstract][Full Text] [Related]
2. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
Temizoz B; Kuroda E; Ohata K; Jounai N; Ozasa K; Kobiyama K; Aoshi T; Ishii KJ
Eur J Immunol; 2015 Apr; 45(4):1159-69. PubMed ID: 25529558
[TBL] [Abstract][Full Text] [Related]
3. TLR9 and STING agonists cooperatively boost the immune response to SARS-CoV-2 RBD vaccine through an increased germinal center B cell response and reshaped T helper responses.
Yang JX; Tseng JC; Tien CF; Lee CY; Liu YL; Lin JJ; Tsai PJ; Liao HC; Liu SJ; Su YW; Hsu LC; Chen JK; Huang MH; Yu GY; Chuang TH
Int J Biol Sci; 2023; 19(9):2897-2913. PubMed ID: 37324951
[TBL] [Abstract][Full Text] [Related]
4. Dual-adjuvant effect of pH-sensitive liposomes loaded with STING and TLR9 agonists regress tumor development by enhancing Th1 immune response.
Kocabas BB; Almacioglu K; Bulut EA; Gucluler G; Tincer G; Bayik D; Gursel M; Gursel I
J Control Release; 2020 Dec; 328():587-595. PubMed ID: 32971199
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with STING and TLR9 agonists promotes synergistic therapeutic efficacy with suppressed cancer-associated fibroblasts in colon carcinoma.
Hajiabadi S; Alidadi S; Montakhab Farahi Z; Ghahramani Seno MM; Farzin H; Haghparast A
Front Immunol; 2023; 14():1258691. PubMed ID: 37901237
[TBL] [Abstract][Full Text] [Related]
6. TLR9 plus STING Agonist Adjuvant Combination Induces Potent Neopeptide T Cell Immunity and Improves Immune Checkpoint Blockade Efficacy in a Tumor Model.
Castro Eiro MD; Hioki K; Li L; Wilmsen MEP; Kiernan CH; Brouwers-Haspels I; van Meurs M; Zhao M; de Wit H; Grashof DGB; van de Werken HJG; Mueller YM; Schliehe C; Temizoz B; Kobiyama K; Ishii KJ; Katsikis PD
J Immunol; 2024 Feb; 212(3):455-465. PubMed ID: 38063488
[TBL] [Abstract][Full Text] [Related]
7. Interferon-γ and granulocyte/monocyte colony-stimulating factor production by natural killer cells involves different signaling pathways and the adaptor stimulator of interferon genes (STING).
Souza-Fonseca-Guimaraes F; Parlato M; de Oliveira RB; Golenbock D; Fitzgerald K; Shalova IN; Biswas SK; Cavaillon JM; Adib-Conquy M
J Biol Chem; 2013 Apr; 288(15):10715-21. PubMed ID: 23443666
[TBL] [Abstract][Full Text] [Related]
8. Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells.
Kitahata Y; Kanuma T; Hayashi M; Kobayashi N; Ozasa K; Kusakabe T; Temizoz B; Kuroda E; Yamaue H; Coban C; Yamamoto T; Kobiyama K; Aoshi T; Ishii KJ
Oncotarget; 2016 Aug; 7(31):48860-48869. PubMed ID: 27384490
[TBL] [Abstract][Full Text] [Related]
9. EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy.
Kapp K; Volz B; Curran MA; Oswald D; Wittig B; Schmidt M
J Immunother Cancer; 2019 Jan; 7(1):5. PubMed ID: 30621769
[TBL] [Abstract][Full Text] [Related]
10. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells.
Tada H; Aiba S; Shibata K; Ohteki T; Takada H
Infect Immun; 2005 Dec; 73(12):7967-76. PubMed ID: 16299289
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral delivery of the chitin-derived C100 adjuvant promotes robust STING, IFNAR, and CD8
Turley JL; Ward RW; Huete-Carrasco J; Muñoz-Wolf N; Roche K; Jin L; Bowie A; Andersson M; Lavelle EC
Cell Rep Med; 2024 May; 5(5):101560. PubMed ID: 38729159
[TBL] [Abstract][Full Text] [Related]
14. Insight into the dichotomous regulation of STING activation in immunotherapy.
Hu Z; Yang Y; Fang L; Zhou J; Zhang H
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):126-137. PubMed ID: 33618600
[TBL] [Abstract][Full Text] [Related]
15. Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.
Kuai R; Sun X; Yuan W; Ochyl LJ; Xu Y; Hassani Najafabadi A; Scheetz L; Yu MZ; Balwani I; Schwendeman A; Moon JJ
J Control Release; 2018 Jul; 282():131-139. PubMed ID: 29702142
[TBL] [Abstract][Full Text] [Related]
16. Antishock Characteristics of Erythrocyte-mediated Endoplasmic Reticulum Stress in Macrophages in Severe Hemorrhagic Shock Environment Based on TLR9-cGAS-STING-IFN Signal Axis.
Kang YQ; Yuan XH; Li ZZ; Wang H; Zhou XF; Wang XX; Zhang ZW; Feng YF; Guo JR
Cell Transplant; 2020; 29():963689720950218. PubMed ID: 33225714
[TBL] [Abstract][Full Text] [Related]
17. Co-operation of α-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model.
Dong T; Yi T; Yang M; Lin S; Li W; Xu X; Hu J; Jia L; Hong X; Niu W
Biochem J; 2016 Jan; 473(1):7-19. PubMed ID: 26450924
[TBL] [Abstract][Full Text] [Related]
18. Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy.
Luo K; Li N; Ye W; Gao H; Luo X; Cheng B
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889509
[TBL] [Abstract][Full Text] [Related]
19. Chemical Biology Perspectives on STING Agonists as Tumor Immunotherapy.
Xuan C; Hu R
ChemMedChem; 2023 Dec; 18(23):e202300405. PubMed ID: 37794702
[TBL] [Abstract][Full Text] [Related]
20. Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity.
Masuda Y; Nawa D; Nakayama Y; Konishi M; Nanba H
J Leukoc Biol; 2015 Dec; 98(6):1015-25. PubMed ID: 26297795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
